✦ LIBER ✦

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

✍ Scribed by Harousseau, J.-L.; Attal, M.; Avet-Loiseau, H.; Marit, G.; Caillot, D.; Mohty, M.; Lenain, P.; Hulin, C.; Facon, T.; Casassus, P.; Michallet, M.; Maisonneuve, H.; Benboubker, L.; Maloisel, F.; Petillon, M.-O.; Webb, I.; Mathiot, C.; Moreau, P.

Book ID: 121863063
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 165 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2009.27.9158

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame